Introduction

Autoimmune disorders affect tens of millions of people worldwide, with conditions such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and type 1 diabetes imposing a substantial burden on patients and healthcare systems. In these diseases, the immune system misidentifies the body’s own tissues as foreign and launches chronic, damaging attacks. Despite decades of research, the underlying mechanisms remain incompletely understood, and many patients do not respond adequately to existing therapies. To unravel this complexity, researchers rely on physiological models—simplified yet powerful tools that mimic aspects of human biology and disease. These models bridge the gap between basic laboratory findings and clinical applications, accelerating the discovery of new treatments and improving our grasp of disease pathways.

Understanding Physiological Models

Physiological models are controlled, reproducible representations of biological systems. They can be living organisms, cellular constructs, or computer algorithms designed to simulate normal or pathological functions. The core value of such models lies in their ability to isolate specific variables, enabling researchers to test hypotheses and interventions in ways that are often impossible, impractical, or unethical with human subjects. By approximating the complex interplay of immune cells, cytokines, and target tissues, these models provide a window into the dynamics of autoimmunity.

Major Types of Physiological Models

Animal Models

Animal models have been cornerstones of autoimmune research for decades. Mice and rats are the most common species because of their genetic tractability, short reproductive cycles, and well-characterized immune systems. Two main approaches are used: spontaneous models, where animals naturally develop autoimmune-like disease, and induced models, where disease is triggered by immunization or genetic manipulation.

  • Genetically engineered models: Mice with targeted gene deletions or insertions allow researchers to study the role of specific immune molecules. For example, the non-obese diabetic (NOD) mouse is a classic model for type 1 diabetes, and lupus-prone strains such as MRL/lpr reveal how defects in apoptosis drive autoimmunity.
  • Induced models: Experimental autoimmune encephalomyelitis (EAE), induced by immunizing animals with myelin antigens, is the most widely used model for multiple sclerosis. Similarly, collagen-induced arthritis in mice recapitulates key features of rheumatoid arthritis.
  • Humanized models: To overcome species differences, immunodeficient mice are engrafted with human immune cells or tissues, creating chimeras that can be used to test human-specific therapeutics and study infections that trigger autoimmunity.

Despite their utility, animal models have limitations. Rodents have different immune receptor repertoires, cytokine profiles, and microbiome compositions compared to humans, leading to discrepancies in drug responses. Many promising treatments that succeeded in mice have failed in clinical trials, highlighting the need for complementary approaches.

In Vitro Models

Cell culture systems offer a more controlled environment to probe cellular and molecular mechanisms. Simple monolayer cultures of immune cells (e.g., T cells, B cells, macrophages) can be stimulated with antigens or cytokines to measure proliferation, cytokine secretion, or cytotoxicity. More advanced systems include:

  • Co-culture models: Multiple cell types—such as T cells and dendritic cells, or immune cells with target tissue cells—are grown together to study cell-cell communication and antigen presentation.
  • Organoids: Three-dimensional structures derived from stem cells that mimic the architecture and function of organs, such as the gut or brain. In autoimmune research, intestinal organoids help investigate how gut permeability and microbial antigens contribute to inflammatory bowel disease.
  • Organ-on-a-chip: Microfluidic devices that simulate the mechanical and biochemical environment of human organs. For example, a “gut-on-a-chip” can model the interaction between immune cells, epithelial cells, and commensal bacteria, providing a platform to test drugs and study barrier function.

These in vitro models reduce reliance on animals and allow high-throughput screening, but they lack the systemic complexity of a whole organism. Systemic factors like hormone fluctuations, neural signals, and distant organ interactions are absent, limiting their predictive power for drug efficacy and toxicity.

In Silico Models

Computational models have emerged as powerful allies, especially as data volumes grow and machine learning techniques advance. In silico models can be broadly divided into:

  • Mechanistic (agent-based) models: Simulating the behavior of individual immune cells and molecules based on known biological rules. These models can replicate the emergence of self-reactive clones, autoantibody production, and tissue damage over time, helping to identify key checkpoints for intervention.
  • Data-driven models: Using historical experimental data, electronic health records, and omics datasets (genomics, proteomics, metabolomics) to predict disease progression or treatment outcomes. Deep learning algorithms can, for instance, identify patterns in T cell receptor sequences that predispose individuals to autoimmunity.
  • Pharmacokinetic/pharmacodynamic (PK/PD) models: These simulate how a drug is absorbed, distributed, metabolized, and eliminated in the body, as well as its effect on immune targets. They help determine optimal dosing regimens before clinical trials.

Computer simulations are cost-effective, scalable, and can explore millions of parameter combinations easily. However, they are only as good as the data and assumptions they are built upon. Incomplete understanding of immune regulatory networks can lead to misleading predictions, necessitating iterative validation with wet-lab experiments.

Applications in Autoimmune Research

Physiological models are deployed across the entire research pipeline. In mechanistic studies, they reveal how regulatory T cells fail, how molecular mimicry between pathogens and self-antigens triggers cross-reactivity, or how cytokines like TNF-α and IL-17 drive tissue inflammation. In biomarker discovery, models allow researchers to track serum autoantibodies, cytokine profiles, or gene expression signatures over the course of disease, helping to identify early indicators that could enable earlier diagnosis.

A crucial application is drug screening. Before a compound enters humans, it is tested in cell-based assays to confirm activity and in animal models to assess efficacy and toxicity. This de-risks clinical development and provides preliminary evidence of target engagement. For instance, the success of anti-TNF biologics in rheumatoid arthritis was built on years of work in animal models and cell cultures that showed TNF-α’s central role in joint destruction.

Advances in Treatment Development

Physiological models have directly contributed to several breakthroughs in autoimmune therapy:

  • Biologics: Monoclonal antibodies that block specific cytokines or immune checkpoints (e.g., anti-TNF, anti-IL-6R, anti-CD20) were developed using iterative testing in cell lines and transgenic mouse models. These drugs have transformed outcomes for many patients with rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
  • Small molecule inhibitors: JAK inhibitors (e.g., tofacitinib) were designed with the help of computational models of kinase activity and then validated in cell-based assays and arthritis models. They now offer oral alternatives to injectable biologics.
  • Cell therapy: Chimeric antigen receptor (CAR) T cells, initially developed for cancer, are being repurposed for autoimmune diseases. Animal models have been essential to test whether CAR T cells can specifically deplete pathogenic B cells or regulatory T cell populations.

Moreover, physiological models enable drug repurposing. By screening existing drugs on in vitro models of autoimmunity, researchers have identified potential new uses for compounds originally developed for other conditions, accelerating clinical translation at lower cost.

Challenges and Limitations

No model is perfect. Animal models often fail to recapitulate the full spectrum of human autoimmune disease because of species-specific immune differences, different microbiota, and the absence of chronic human environmental triggers. In vitro systems lack the systemic feedback loops—such as the hypothalamic-pituitary-adrenal axis—that influence immune responses. In silico models depend on high-quality, unbiased data, which is often scarce for rare autoimmune variants.

Another major challenge is the heterogeneity of autoimmune patients. Two individuals with the same diagnosis may have very different genetic backgrounds, autoantibody profiles, and clinical courses. Most models represent an “average” disease state, making personalized predictions difficult. While humanized mice and patient-derived organoids are steps toward personalization, they remain labor-intensive and expensive.

Ethical Considerations

The use of animal models in autoimmunity research raises important ethical questions. In many countries, the “3Rs” (Replacement, Reduction, Refinement) guide animal experimentation: researchers must replace animals with alternative methods when possible, reduce the number used, and refine procedures to minimize suffering. Physiological models like organoids and computer simulations contribute to replacement, although some questions can only be answered using whole-body systems. Efforts to improve transparency, encourage non-animal innovations, and audit animal welfare are ongoing across research institutions.

Patient-derived samples also raise ethical considerations regarding informed consent, genetic privacy, and the return of incidental findings. As models become more personalized, these issues will require careful governance.

Future Directions

The future of autoimmune disease modeling lies in integration and personalization. Multi-scale models that combine molecular, cellular, tissue, and whole-organism data are being developed using artificial intelligence and high-performance computing. These models could predict an individual’s risk of developing an autoimmune flare, identify the optimal biologic for their immune profile, and simulate the long-term effects of combination therapies.

Induced pluripotent stem cells (iPSCs) from patients can be differentiated into immune cells or target tissues, creating “disease-in-a-dish” models that capture a person’s unique genetic and epigenetic landscape. Combining iPSC-derived cells with microfluidic organ chips could produce platforms that mimic patient-specific immune interactions.

Advances in multi-omics—integrating genomics, transcriptomics, proteomics, metabolomics, and microbiome data—will feed these models with richer input, enabling a more holistic view of disease emergence and progression. Machine learning algorithms can sift through these vast datasets to find novel disease subtypes or drug targets that would be invisible to traditional approaches.

Finally, regulatory agencies are beginning to accept evidence from well-validated in silico and in vitro models as support for investigational new drug applications. This trend will likely accelerate, reducing the number of animals used and speeding up the delivery of safe, effective therapies to patients.

Conclusion

Physiological models are indispensable for untangling the mechanisms of autoimmunity and developing safer, more effective treatments. No single model can capture every aspect of these complex diseases, but by combining animal, cellular, and computational approaches, researchers can overcome the limitations of each. Continued innovation—especially in personalized and multi-scale modeling—promises to transform the diagnosis and management of autoimmune disorders, ultimately improving outcomes for millions of patients. As the field moves forward, ethical commitment to animal welfare and data transparency will remain essential to maintain public trust and scientific rigor.

For further reading on the use of animal models in autoimmune research, the Nature Reviews Drug Discovery article on animal models of autoimmune disease provides a comprehensive overview. Advances in organ-on-chip technology are reviewed in a recent Science article on microphysiological systems. Those interested in the ethical guidelines can consult the NC3Rs website for the 3Rs framework.